Print Print   Email Email

The investor pages that follow are your resource for financial information about Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.

Recent Releases

Jul 14, 2010
Safety and Tolerability of Dimebon for up to 26 Weeks in Patients with Mild-to-Moderate Alzheimer's Disease

Jun 7, 2010
American Society of Clinical Oncology (ASCO) Annual Meeting

more »

Investor and Media Contacts

For Investors
investors@medivation.com

For Media
media@medivation.com